In EBV-positive HIV-associated DLBCL, mutations in JAK/STAT pathway also leads to abnormal activation and elevated expression of downstream oncogenes, such as c-MYC, thereby resulting in the progression of malignant tumors [37, 38]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.